Related Experiment Videos
Myocardial infarction size: measurement and modification
Insights
Acute myocardial infarction deaths often result from heart "power failure." Early interventions may limit myocardial cell death and infarct size, but this remains in clinical research, not routine use.
Area of Science:
- Cardiology
- Cardiovascular Research
Background:
- Acute myocardial infarction (AMI) frequently leads to in-hospital mortality via severe congestive heart failure and cardiogenic shock.
- This
- power failure
- syndrome stems from extensive myocardial cell loss, which occurs sequentially over hours.
Purpose of the Study:
- To explore interventions aimed at limiting infarct size during the early phase of acute myocardial infarction.
- To assess the potential of altering the fate of ischemic myocardium surrounding the central necrotic zone.
Main Methods:
- Development of noninvasive techniques for infarct size assessment, including ST-segment mapping, serial creatine phosphokinase measurements, and radionuclide myocardial imaging.
- Evaluation of interventions in animal models and preliminary studies in humans.
Main Results:
- Animal studies indicate several interventions can limit infarct size.
- Preliminary human data suggest certain interventions may also reduce infarct size, though extensive research is still needed.
Conclusions:
- Understanding the course of AMI and the effects of therapies is crucial.
- Interventions to limit infarct size show promise but are currently confined to clinical research and not yet for routine patient care.
Abstract:
The majority of in-hospital deaths from acute myocardial infarction occur as a result of the "power failure" syndrome (severe congestive heart failure and cardiogenic shock), which results from extensive loss of myocardium. The death of myocardial cells is sequential over many hours. Surrounding the central zone of necrosis in an acute myocardial infarction is a zone of ischemic myocardium whose fate might be altered by interventions during the early phase of the infarction. ST-segment mapping, serial measurement of the serum concentration of creatine phosphokinase and myocardial imaging by means of radionuclides are being developed for the noninvasive assessment of infarct size in animals and humans. A number of interventions appear to limit infarct size in animals. There have been relatively few studies in humans to date, but preliminary results suggest that infarct size might be limited by certain interventions. The research has provided important practical benefits in terms of understanding the course of acute myocardial infarction and the potential effects of conventional therapies. For the present, interventions designed to limit infarct size remain in the realm of clinical research; routine clinical use would be inappropriate.